Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

According to a 2024 study from Hims & Hers, The Shape of America, 83% of Americans are not at the weight they'd like to be. The average amount of weight folks are looking to lose? 42 pounds ... So, ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway out of the eye is too small, she explained. This could happen when glucose ...

The bar chart below compares the rate of NAION ... Prof Sattar says people who are not obese but access semaglutide privately to lose weight may suffer this side effect, as he is not familiar ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to treat ... This release of GLP-1 also helps suppress appetite, helping people lose weight. By reducing obesity and ...

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...